{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-8497", "postId": 8497, "name": "Boston Scientific Corporation", "description": "If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation (\u201cBoston Scientific\u201d or the \u201cCompany\u201d) (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose true state of Boston Scientific\u2019s U.S. EP segment; notably, that management was aware that the segment\u2019s growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to Defendants\u2019 statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific\u2019s net income miss and underwhelming guidance for the first half of fiscal 2026. Lead Plaintiff Deadline: May 4, 2026 \u00a0Call\u00a0Partner Josh Wilson\u00a0at\u00a0877-247-4292\u00a0or\u00a0212-983-9330 (Ext. 1310) Or\u00a0submit your information below\u00a0to learn about your rights.", "identifier": "BSX", "legal": { "court": "United States District Court for the District of Massachusetts", "jurisdiction": "Federal (United States), federal securities laws" }, "classPeriod": { "start": "07/23/2025", "end": "02/03/2026" }, "leadPlaintiffDeadline": "05/04/2026", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/boston-scientific-corporation/", "canonicalUrl": "https://faruqilaw.com/case/boston-scientific-corporation/", "datePublished": "2026-03-06T17:55:31+00:00", "dateModified": "2026-03-06T17:55:31+00:00", "associatedOrganization": { "@id": "case-8497-org" }, "legalService": { "@id": "case-8497-legalservice" }, "hasPart": [ { "@id": "case-8497-faq" }, { "@id": "case-8497-press-list" } ], "legalRepresentation": [ { "@id": "case-8497-attorney-516" }, { "@id": "case-8497-attorney-506" } ] }, { "@type": "Organization", "@id": "case-8497-org", "name": "Boston Scientific Corporation", "identifier": "BSX", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "url": "https://www.bostonscientific.com/en-US/home.html" }, { "@type": "LegalService", "@id": "case-8497-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-8497-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-8497-legalservice" } }, { "@type": "Person", "@id": "case-8497-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-8497-legalservice" } }, { "@type": "FAQPage", "@id": "case-8497-faq", "mainEntity": [ { "@type": "Question", "name": "Why is Boston Scientific facing a securities class action lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Investors allege Boston Scientific made misleading statements about the strength and sustainability of growth in its U.S. electrophysiology (EP) segment before reporting weaker results." } }, { "@type": "Question", "name": "What is the U.S. electrophysiology segment at Boston Scientific?", "acceptedAnswer": { "@type": "Answer", "text": "The EP segment includes products used to diagnose and treat heart rhythm disorders. It has been a key driver of growth for the company\u2019s cardiovascular business." } }, { "@type": "Question", "name": "Why were investors surprised by Boston Scientific\u2019s earnings results?", "acceptedAnswer": { "@type": "Answer", "text": "Plaintiffs say the company expressed strong confidence in continued EP growth, leaving analysts and investors unprepared for the earnings miss." } }, { "@type": "Question", "name": "What are investors alleging about Boston Scientific\u2019s EP growth?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit claims management knew the segment\u2019s growth rate was unsustainable and approaching a slowdown sooner than investors expected." } }, { "@type": "Question", "name": "How do securities class action lawsuits start?", "acceptedAnswer": { "@type": "Answer", "text": "They typically begin when investors file a complaint alleging that a company made false or misleading statements or failed to disclose important information that affected the stock price." } }, { "@type": "Question", "name": "What is a corrective disclosure in a securities lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "A corrective disclosure is new information released to the market that reveals the truth about prior misleading statements, often triggering a stock price drop." } }, { "@type": "Question", "name": "What happens during the discovery phase of a securities lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "During discovery, both sides exchange documents, emails, financial records, and testimony to gather evidence related to the alleged misconduct." } }, { "@type": "Question", "name": "How do investors receive money from a securities settlement?", "acceptedAnswer": { "@type": "Answer", "text": "If a settlement is approved by the court, investors submit a claim form documenting their trades, and payments are distributed from the settlement fund." } } ] }, { "@type": "NewsArticle", "@id": "case-8497-press-1", "headline": "Boston Scientific Earnings Beat Estimates. It\u2019s the Worst Stock in the S&P 500 Today.", "url": "https://www.barrons.com/articles/boston-scientific-earnings-stock-price-0ffe2c6f?gaa_at=eafs&gaa_n=AWEtsqcf9U-Nf0V14Bu9PQJ92z09_M6hI6Da4wW0fBNVeMaS4NUDbDGqa830mY8i36A%3D&gaa_ts=69ab1822&gaa_sig=8LwDwh8S6fxrIbVArvXudbGdzcKGInuoOSUcgY6xPd2QN-DXnHrZRWq9GpQaQpaM4kG2aItMFJyKkAmoG96-BA%3D%3D", "datePublished": "2026-02-04" }, { "@type": "NewsArticle", "@id": "case-8497-press-2", "headline": "Boston Scientific stock plunges 17% on new competition in key tech", "url": "https://www.startribune.com/boston-scientific-stock/601576627", "datePublished": "2026-02-04" }, { "@type": "NewsArticle", "@id": "case-8497-press-3", "headline": "Why Boston Scientific Stock Plummeted Today", "url": "https://www.fool.com/investing/2026/02/04/why-boston-scientific-stock-plummeted-today/", "datePublished": "2026-02-04" }, { "@type": "NewsArticle", "@id": "case-8497-press-4", "headline": "Boston Scientific Hits An 18-Month Low On A 'Sore Spot' For Its Most Hyped Device", "url": "https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q4-2025/", "datePublished": "2026-02-04" }, { "@type": "ItemList", "@id": "case-8497-press-list", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "case-8497-press-1" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "case-8497-press-2" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "case-8497-press-3" } }, { "@type": "ListItem", "position": 4, "item": { "@id": "case-8497-press-4" } } ] } ] }

Boston Scientific Corporation

Boston Scientific Corporation

Join Action
Case Details
Ticker BSX
Class Period 07/23/2025 - 02/03/2026
Lead Plaintiff Deadline 05/04/2026
Days Left to Seek Plaintiff
3

If you are a Boston Scientific investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose true state of Boston Scientific’s U.S. EP segment; notably, that management was aware that the segment’s growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to Defendants’ statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific’s net income miss and underwhelming guidance for the first half of fiscal 2026.

📞 Lead Plaintiff Deadline: May 4, 2026

💻 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action
Boston Scientific Corporation
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
New York
685 Third Avenue 26th Floor New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771